This finding may also provide a potential therapeutic strategy for scRMS characterized by these fusion proteins, as well as a range of other tumors carrying NCOA1/2/3 rearrangements, including uterine sarcoma (Niu et al., 2023), mesenchymal chondrosarcoma (Wang et al., 2012; Tanaka et al., 2023), soft tissue angiofibroma (Jin et al., 2012; Yamashita et al., 2023), ovarian sex cord tumors (Goebel et al., 2020; Lu et al., 2023), leukemia (Strehl et al., 2008), colon cancer (Yu et al., 2016), and ependymoma (Tauziède-Espariat et al., 2021; Tomomasa et al., 2021). This evidence concerns the gene NCOA1 and uterine corpus sarcoma.